Tarsus Pharmaceuticals Inc TARS.OQ TARS.O is expected to show a rise in quarterly revenue when it reports results on November 4 for the period ending September 30 2025
The Irvine California-based company is expected to report a 139.5% increase in revenue to $115.222 million from $48.12 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Tarsus Pharmaceuticals Inc is for a loss of 35 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is $85.00, about 18.9% above its last closing price of $68.96
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.39 | -0.40 | -0.48 | Missed | -20.1 |
Mar. 31 2025 | -0.70 | -0.73 | -0.64 | Beat | 12.4 |
Dec. 31 2024 | -0.67 | -0.74 | -0.60 | Beat | 19.2 |
Sep. 30 2024 | -0.97 | -0.97 | -0.61 | Beat | 37.3 |
Jun. 30 2024 | -0.90 | -0.92 | -0.88 | Beat | 4.8 |
Mar. 31 2024 | -1.21 | -1.20 | -1.01 | Beat | 16.2 |
Dec. 31 2023 | -1.39 | -1.36 | -1.31 | Beat | 3.9 |
Sep. 30 2023 | -1.29 | -1.37 | -1.28 | Beat | 6.3 |
This summary was machine generated October 31 at 21:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments